One potential harm is that this technique still misses some malignant lesions.
The actual cost implications of the new test are anything but clear based on this news release.
News releases about new diagnostic tests will be read by patients and their families and should strive to discuss the impact of early diagnosis, beyond the potential benefits for research.
The two major outcomes measured in this study (pain control and quality of life) were measured using questionnaires which are highly subjective and difficult to reproduce. There was no control or comparison group.
Only human clinical trials can show if animal results will be ever be replicated in people.
The news releases also left out mention of several major conflicts of interest.
The release provides a lot of information on how the procedure works, and why it’s needed. However, the release left out some key details. Are there risks associated with this technique? What sort of expenses are involved for patients? What sort of questions and concerns are still outstanding?
The news release offers unwarranted medical advice while omitting any caution about the limitations of using mouse studies to predict human outcomes.
The study involved just 117 women at a single hospital.
The release is strong on context and explaining the procedure but would have been more informative with a more thorough discussion of harms and use of actual patient data rather than relative risk numbers when describing benefits.